HemOnc Today New York
HemOnc Today New York
April 06, 2016
20 min watch

VIDEO: Speaker recommends shift in focus from cure to impact for BCC

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

NEW YORK — Aleksandar Sekulic, MD, PhD, associate director of the Center for Individualized Medicine at Mayo Clinic in Scottsdale, Arizona, presented updates on surgical and systemic therapy options to treat advanced basal cell carcinoma at HemOnc Today Melanoma and Cutaneous Malignancies.

Because of previous unmet medical needs in this area, researchers have focused on Hedgehog pathway inhibition. Sekulic discussed the management of toxicities, therapeutic resistance and the next steps in how to treat locally advanced and metastatic basal cell carcinoma with Hedgehog pathway inhibitors.

“With a drug class that works well but does have toxicities over the long term, sometimes refocusing from ‘cure at any cost’ to improvement may be useful,” Sekulic said. “This is also important for neoadjuvant use. Can you shrink the tumor and make the surgery smaller? Can you turn operable into inoperable? That is a possibility.”